

**How to Use
 This Document**

This document is intended to summarize updates to the Wellfleet Rx National Preferred Formulary since the last formulary print version from 4/1/2021. These updates include both positive changes to existing formulary statuses and updates for newly approved medications. For all other medications not listed below, refer to the July 2021 National Preferred Formulary for information on formulary status

Positive Changes – Effective 7/1/2021 for All Users

Move to Preferred Status

Multivitamins	O-CAP Prenatal (GPID 95411)
Antibiotics	CIPRO SUSP (BRAND)
Blood Glucose Meters	FREESTYLE LIBRE 2 SENSOR

Move to Non-Preferred Status

These products were previously excluded medications and were recently moved to non-preferred status (with PA) as part of the creation of the Rare Disease Care Rx Program; therefore, this is considered a positive change.

RARE DISEASE CARE RX PROGRAM DRUGS	BERINERT, EXONDYS-51, VYONDYS-53, ACTHAR, SPINRAZA, LUXTURNA, ORLADEYO, OXBRYTA, VILTEPSO, KORLYM, RAVICTI
---------------------------------------	--

Update Step Therapy Requirements

Osteoporosis	Risedronate (generic Actonel) – update requirement to T/F of one alternative rather than two as currently programmed
--------------	--

Negative Changes –

These changes took effect in May 2021 as part of a low net cost strategy. No new negative changes are occurring as part of the July 2021 formulary update

Move to Excluded (Preferred Product)

Multiple Sclerosis Therapy	TECFIDERA*
Opioid Analgesics	INTRAVENOUS MORPHINE SULFATE/0.9% NACL (multiple iv and oral alternatives)

Please note: The bolded medications are brands with a generic available.

**This change occurred as of 4/1/2021. All utilizers were notified via mail; existing users were grandfathered through 5/1/2021 except members using Specialty 360. Brand Tecfidera was excluded driving members to use generic dimethyl fumarate. This is only listed here for reference purposes.*

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.